TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23441920

Group type: EXPERIMENTAL
Intervention: Non-surgical therapy plus azithromycin (AZ-Sca)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-surgical therapy plus placebo (PB-Sca)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Supragingival prophylaxis plus azithromycin (AZ-Pro)
Number of subjects: 105
Study: 21349204

Group type: EXPERIMENTAL
Intervention: Tele-health program (MoodCare) consisting of up to 10 × 30-40 minute structured telephone sessions delivered by registered psychologists, focusing on depression management and lifestyle factors.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (UC) control group receiving standard medical care.
Number of subjects: 100
Study: 19055289

Group type: EXPERIMENTAL
Intervention: Compound anesthesia of transcutaneous electrical point stimulation and Remifentanil
Number of subjects: 60
Study: 16541377

Group type: EXPERIMENTAL
Intervention: Prior Exercise (PE) - 10 min at 60% of MAP followed by 4 intervals of 30-s cycling at 100% MAP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prior Exercise (PE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No Prior Exercise (NPE)
Number of subjects: 15
Study: 14601750

Group type: EXPERIMENTAL
Intervention: Proposed test for survival-time distributions with dependent censoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized log-rank test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary log-rank test
Number of subjects: 0
Study: 11073741

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day; maximum, 500 mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ceftriaxone (75 mg/kg/day; maximum, 2.5 g/day)
Number of subjects: 108
Study: 9189304

Group type: EXPERIMENTAL
Intervention: 3S (multiple set heavy-resistance exercise)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1S (single set heavy-resistance exercise)
Number of subjects: 8
Study: 8467025

Group type: EXPERIMENTAL
Intervention: Midazolam (50 micrograms/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 53
Study: 31909417

Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation during order entry
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for prophylaxis
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for empiric antibiotics
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for definitive antibiotics
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Survey of prescribers regarding documentation burden
Number of subjects: 180
Study: 30835308

Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention (n=204) including behavioral weight loss treatment, problem-solving therapy, and as-needed antidepressant medications
Number of subjects: 409

Group type: COMPARATOR
Intervention: Usual care control group (n=205)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention (n=204)
Number of subjects: 409
Study: 28116579

Group type: EXPERIMENTAL
Intervention: Brief intervention involving four group sessions of motivational interviewing and cognitive behavioural therapy, initiated 4 weeks prior to release.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamphlet and brief verbal intervention at baseline assessment (Control group).
Number of subjects: 0
Study: 25323237

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure (10 μg · m(‐3))
Number of subjects: 10377

Group type: EXPERIMENTAL
Intervention: PM10 exposure (10 μg · m(‐3))
Number of subjects: 10377

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (5 μg · m(‐3))
Number of subjects: 10377
Study: 24428857

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg body weight, 100 mg/mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 100
Study: 21407047

Group type: EXPERIMENTAL
Intervention: Continuation of risperidone for the next 32 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone for the next 16 weeks followed by placebo for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for the next 32 weeks
Number of subjects: 0
Study: 20513572

Group type: EXPERIMENTAL
Intervention: 4 locking screws in the distal row of the plate (Group a)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4 locking screws alternately in the distal and proximal rows (Group b)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3 locking screws in the proximal row (Group c)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 7 locking screws filling all screw holes in the distal and proximal rows (Group d)
Number of subjects: 32
Study: 17418728

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) solution to bring down the hematocrit to 45%
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% dextrose solution
Number of subjects: 50
Study: 15466458

Group type: COMPARATOR
Intervention: CMS patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HA controls
Number of subjects: 22
Study: 12060503

Group type: EXPERIMENTAL
Intervention: Doublebase (novel hydro-gel emollient)
Number of subjects: 78
Study: 10682436

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (surgical group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (non-pregnant women)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (early pregnancy progression)
Number of subjects: 66
Study: 7615947

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8654
Study: 2515215

Group type: EXPERIMENTAL
Intervention: Active patch (N = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patch (N = 9)
Number of subjects: 20
Study: 326447

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (dummy preparation)
Number of subjects: 0
Study: 30883284

Group type: EXPERIMENTAL
Intervention: Check Yourself tool + SBHC visit
Number of subjects: 148

Group type: COMPARATOR
Intervention: SBHC visit without Check Yourself tool
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study: 29436364

Group type: EXPERIMENTAL
Intervention: WAVES intervention (12-month intervention promoting healthy eating and physical activity)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1467
Study: 27521672

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DXI; Ozurdex) in combination with ranibizumab (Lucentis)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ranibizumab (Lucentis) alone
Number of subjects: 10
Study: 24932567

Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance (SFM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Behavioral skills maintenance treatment (BSM)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 22011511

Group type: EXPERIMENTAL
Intervention: Carisbamate 200 mg twice-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carisbamate 600 mg twice-daily
Number of subjects: 0
Study: 19581013

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with AT allele (GC/AT+AT/AT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with GC/GC genotype
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with GC/GC genotype, negative p53 and weak survivin expression
Number of subjects: 138

Group type: COMPARATOR
Intervention: Non-radiotherapy group
Number of subjects: 138
Study: 17180159

Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 6 months by HCV patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 1 week by healthy subjects
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (nonresponder patients without FSMP)
Number of subjects: 39
Study: 15530294

Group type: EXPERIMENTAL
Intervention: LHE plus salicylic acid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Salicylic-acid cream alone
Number of subjects: 13
Study: 11797074

Group type: EXPERIMENTAL
Intervention: 5 mg nicotine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9549664

Group type: EXPERIMENTAL
Intervention: Conventional formulation (CF) venlafaxine 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extended-release formulation (XR) venlafaxine 75 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous venlafaxine 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7654925

Group type: EXPERIMENTAL
Intervention: Nursing advice through direct interview or telephone call to non-vaccinated patients.
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Direct interview back-up at the Nursing station.
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Overall retrieval effectiveness of nursing intervention.
Number of subjects: 378
Study: 2659953

Group type: EXPERIMENTAL
Intervention: Calcitriol 2 mcg/d for 7 days, followed by 100 U/d Salmon Calcitonin + 1 g/d Calcitonin for 21 days, followed by Calcium alone for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salmon Calcitonin alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium alone for 1 year
Number of subjects: 20
Study: 31050562

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Myofascial release (from day 3 to day 6 post-surgery)
Number of subjects: 80
Study: 31455404

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 439
Study: 27253835

Group type: EXPERIMENTAL
Intervention: Hip Thrust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Front Squat
Number of subjects: 0
Study: 25510441

Group type: EXPERIMENTAL
Intervention: Pelvic lead shielding
Number of subjects: 332
Study: 23560454

Group type: EXPERIMENTAL
Intervention: IV ketamine (0.5 mg/kg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 114
Study: 22938659

Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (25-35 ml×kg(‐1)×d(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional fluid management (40-50 ml×kg(‐1)×d(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Restrictive fluid management
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional fluid management
Number of subjects: 30
Study: 17989993

Group type: EXPERIMENTAL
Intervention: Ethanol-containing disinfectant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2-propanol-containing disinfectant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of ethanol and 2-propanol disinfectants
Number of subjects: 14
Study: 17472545

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study: 16087989

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Total Fat Mass
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Fat-adjusted appendicular lean mass (aLM)
Number of subjects: 286
Study: 11799501

Group type: EXPERIMENTAL
Intervention: Intrathecal opioids
Number of subjects: 7

Group type: COMPARATOR
Intervention: Epidural local anesthetics
Number of subjects: 7
Study: 9892878

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 4 days
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 7 days
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 10 days
Number of subjects: 165
Study: 7740846

Group type: EXPERIMENTAL
Intervention: 500 micrograms L-thyroxine injected intraamniotically
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group of prematures selected according to gestational age
Number of subjects: 40
Study: 1723379

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms inhaled twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular beta 2‐agonist therapy
Number of subjects: 0
Study: 6126423

Group type: COMPARATOR
Intervention: Cimetidine 1000 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oxmetidine 800 mg/day
Number of subjects: 99
Study: 30893150

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in the STRASS-1 study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy for high-grade liposarcoma and leiomyosarcoma of the retroperitoneum in the upcoming STRASS-2 study
Number of subjects: 0
Study: 28278301

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study: 26462680

Group type: EXPERIMENTAL
Intervention: Customized nasal mask cushion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional nasal mask cushion
Number of subjects: 40
Study: 23242490

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 20
Study: 21762150

Group type: EXPERIMENTAL
Intervention: 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride dentifrice
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sodium fluoride/silica control dentifrice
Number of subjects: 224
Study: 19500080

Group type: EXPERIMENTAL
Intervention: Fast-edit film (3.5 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-edit film (3.5 minutes)
Number of subjects: 0
Study: 16911869

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg dry powder inhalation twice daily for 8 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 204
Study: 15038626

Group type: EXPERIMENTAL
Intervention: Antihypertensive agent therapy (AHA)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Lifestyle modification (LSM)
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1121
Study: 11176085

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 54
Study: 9625400

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg, once daily at bedtime)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study: 8174730

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 3 months
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 3420170

Group type: EXPERIMENTAL
Intervention: Rolfing pelvic mobilization session (45 minutes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control session without manipulation (45 minutes)
Number of subjects: 32
Study: 30376086

Group type: EXPERIMENTAL
Intervention: IPV-bOPV
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: IPV-only (IPV-IPV-IPV)
Number of subjects: 152

Group type: COMPARATOR
Intervention: mOPV2 (challenge dose)
Number of subjects: 152
Study: 28216065

Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study: 26333543

Group type: EXPERIMENTAL
Intervention: EBFR of 200 mL/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EBFR of 300 mL/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EBFR of 200, 300 and 400 mL/min
Number of subjects: 22
Study: 23656365

Group type: EXPERIMENTAL
Intervention: Experimental group (received HIV survey post-test)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Waitlist control group (received neutral, non-HIV-related survey pre-test)
Number of subjects: 143
Study: 21827531

Group type: EXPERIMENTAL
Intervention: Brief Intervention for Alcohol Use
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 95
Study: 18783971

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg kg(‐1) at induction, 1 mg kg(‐1) h(‐1) during surgery, then 1 mg kg(‐1) during 24 h; n=42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Normal saline (placebo; n=44)
Number of subjects: 86
Study: 16924687

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) in patients with FM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PSQI component scores in patients with FM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Specific sleep difficulties in patients with FM
Number of subjects: 30
Study: 15272090

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy and sertraline
Number of subjects: 858

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 858
Study: 11359393

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine 1% cream
Number of subjects: 129

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 129
Study: 9225847

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen
Number of subjects: 1
Study: 7967424

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (CESS 86)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early irradiation (CESS 86)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High quality radiation therapy (CESS 86)
Number of subjects: 0
Study: 3191933

Group type: EXPERIMENTAL
Intervention: Defibrotide (single infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31465791

Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (intraurethral aqueous gel)
Number of subjects: 18
Study: 28616887

Group type: EXPERIMENTAL
Intervention: Computer-based training (CBT only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-based training with homecare worker peer facilitation (CBT + peer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25646883

Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to blood donors (n=6298)
Number of subjects: 11867

Group type: COMPARATOR
Intervention: Usual procedure (control group, n=5569)
Number of subjects: 11867

Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to blood donors (n=81 who chose testing)
Number of subjects: 11867
Study: 23731775

Group type: EXPERIMENTAL
Intervention: Candesartan 8mg once daily for 3-6 weeks before ECV and 16mg once daily for 6 months after ECV
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo for 3-6 weeks before ECV and placebo for 6 months after ECV
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Baseline YKL‐40 levels
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: YKL‐40 levels at end of study
Number of subjects: 171
Study: 21613787

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 458

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 458
Study: 18665413

Group type: EXPERIMENTAL
Intervention: 4 meals/week fatty fish (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 4 meals/week lean fish (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control diet including lean meat (n = 10)
Number of subjects: 33
Study: 16547838

Group type: EXPERIMENTAL
Intervention: Novel instrument for self-quantification of energy expenditure
Number of subjects: 418
Study: 15217041

Group type: EXPERIMENTAL
Intervention: Experimental [Boredom] group (completed a 15-min. 'boredom' test)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (participated in relaxing activities)
Number of subjects: 56
Study: 11111140

Group type: EXPERIMENTAL
Intervention: Multiple vascular risk factors (2 or more)
Number of subjects: 0
Study: 8874455

Group type: COMPARATOR
Intervention: Radiotherapy alone (45 Gy in twenty or twenty-five fractions over 4-5 weeks)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT) with radiotherapy, 5-fluorouracil (1000 mg/m2 for 4 days or 750 mg/m2 for 5 days), and mitomycin (12 mg/m2 on day 1 of the first course)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 585
Study: 1531573

Group type: EXPERIMENTAL
Intervention: Clindamycin plus cefamandole
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clindamycin plus doxycycline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Laparoscopic grading of severity
Number of subjects: 33
Study: 6401351

Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg per day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 31056997

Group type: EXPERIMENTAL
Intervention: Peer-led group program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 42
Study: 27903568

Group type: EXPERIMENTAL
Intervention: Transendocardial delivery of bone marrow CD133+ cells (n=16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 31
Study: 26159014

Group type: EXPERIMENTAL
Intervention: Qi benefiting blood activating method (QB-BAM) with Shengmai Injection and Tanshinone IIA Injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy for AECOPD
Number of subjects: 60